Life Science

Potently and irreversibly inactivates SAH hydrolase (Ki = 8.39 nM) has antitumor activity against mouse leukemia L1210 cells and broad-spectrum antiviral activity.

A potent inhibitor of Mdm2-p53 binding (IC₅₀ = 0.09 &microM) induces the expression of p53-regulated genes and exhibits potent antiproliferative activity in cells with functional p53 also called enantiomer a based on the elution

A potent inhibitor of Mdm2-p53 binding (IC₅₀ = 0.09 &microM) induces the expression of p53-regulated genes and exhibits potent antiproliferative activity in cells with functional p53 also called enantiomer a based on the elution

A potent inhibitor of Mdm2-p53 binding (IC₅₀ = 0.09 &microM) induces the expression of p53-regulated genes and exhibits potent antiproliferative activity in cells with functional p53 also called enantiomer a based on the elution

A potent inhibitor of Mdm2-p53 binding (IC₅₀ = 0.09 &microM) induces the expression of p53-regulated genes and exhibits potent antiproliferative activity in cells with functional p53 also called enantiomer a based on the elution

An enantiomer of C75, which in racemic form is a stable FAS inhibitor that when administered leads to profound weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.

An enantiomer of C75, which in racemic form is a stable FAS inhibitor that when administered leads to profound weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.

An anticoagulant differs from (+)-warfarin by being five times more potent as a vitamin K antagonist has a shorter terminal elimination half-life (24-33 hours) than (+)-warfarin (35-58 hours).

An anticoagulant differs from (+)-warfarin by being five times more potent as a vitamin K antagonist has a shorter terminal elimination half-life (24-33 hours) than (+)-warfarin (35-58 hours).

An anticoagulant differs from (+)-warfarin by being five times more potent as a vitamin K antagonist has a shorter terminal elimination half-life (24-33 hours) than (+)-warfarin (35-58 hours).

An anticoagulant differs from (+)-warfarin by being five times more potent as a vitamin K antagonist has a shorter terminal elimination half-life (24-33 hours) than (+)-warfarin (35-58 hours).

An aminoalkylindole derivative which acts as a competitive neutral antagonist of the human cannabinoid CB2 receptor, blocking both the stimulating action of CP 55,940 (pA2 = 6.1) and the inverse agonism of SR 144528 (pEC50 = 5.3).